Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.

MLA

Bender JL, et al. “Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients with Refractory Solid Tumors: A Children’s Oncology Group Study.” Journal of Clinical Oncology, vol. 26, no. 3, Jan. 2008, pp. 399–405. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=105862139&authtype=sso&custid=ns315887.

APA

Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ, & Children’s Oncology Group Study. (2008). Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. Journal of Clinical Oncology, 26(3), 399–405.

Chicago

Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, et al. 2008. “Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients with Refractory Solid Tumors: A Children’s Oncology Group Study.” Journal of Clinical Oncology 26 (3): 399–405. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=105862139&authtype=sso&custid=ns315887.